Skeletal and systemic disease may be reflected in profound alterations of the metabolism of the bone salts. In human skeletal disease attention has focused, for the most part, on the altered metabolism of calcium. Several studies indicate that strontium may have a metabolic pathway similar to that of calcium and that radiostrontium, because of its ease of measurement, might be a convenient indicator for observing the transfer of calcium through the calcium-containing compartments of the body.
Metabolic balances for stable calcium, phosphorus and nitrogen were measured according to methods previously described (1) . All determinations for calcium were performed in duplicate on 2 different aliquots of each specimen.
Isotopic measurements. Since all samples contained both Cae and Sr' in varying quantities, the following method was employed to determine the amount of each isotope in each specimen.
Sr"5 was measured directly in a well-type scintillation counter equipped with a pulse-height analyzer. This apparatus had a background of 8 cpm, a counting efficiency of 16.4 per cent for Sr' (sensitivity = 360,000 cpm per mc), and completely excluded radiation from Ca45. Duplicate samples of 2 ml of serum, acidified urine, and redissolved stool ash were measured for 10 minutes and compared with standards made up from the same Sr'5 solution as that used for the administered dose. There was a statistical counting error of 2 per cent, except for specimens from the latter phases of each study, when the probable error of measurement of Sr'5 was as high as 6 per cent.
Specimens for the determination of Ca" were prepared by a modification of the method of Maletskos (1). It was repeatedly found that the Sr'5 present, as well as the Ca', was completely recovered on the planchets. These planchets, containing both Ca" and Sr'5, were counted in a gas-flow counter (SC-50 Tracerlab) which had an efficiency of 20.9 per cent (sensitivity=460,000 cpm per mc) for Ca45 and only 1 
STRONTIUM AND CALCIUM METABOLISM IN BONE DISEASES
When calculated for specific times the resulting curve represents the ratio between the curve of isotope retention and the specific activity curve. The dimension of the pool is in grams.
The calcium "pool" is a quantitative approximation of the amount of body calcium that has mixed with the administered labeled isotope at a specific time, and provides a value for comparison of patients with different bone diseases. Since the skeleton contains 99 per cent of the total body calcium, calcium "pools"-especially at later times-are related to the mass of bone that has mixed. For each isotope, "pool" sizes based on urine and serum specific activities were determined at 3-day intervals.
RESULTS
Isotopic excretion data. In all disease states and at all times, the patient retained more Ca45 than Sr85; the ratio of retention of Ca45 to that of Sr85 varied from 1.1 to 5.7. Figure 2 and Tables III  and IV show that 1.9 to 8.1 times more Sr85 than Ca45 appeared in the urine. Sr85 elimination, fecal loss of Sr85 was substantial. As much as 30 per cent of the administered dose was lost by this route within the first 21 days. On the other hand, fecal losses of each isotope were equal.
There was no correlation between the total labeled calcium or strontium and the total stable calcium excreted.
Specific activities. Urine and serum specific activity curves of characteristic form are illustrated in Figures 3 through 6 . Initially, Sr85 "specific activity" in the urine was three to eight times larger than that of Ca45. As each study progressed, the difference between the two values decreased so that the respective urine specific activity curves converged and in some cases intersected ( Figure 5 ).
The serum specific activities for each labeled isotope were initially the same and fell close together for at least the first 24 hours and in some cases for the next six days (Figure 4 ). There- after Sr85 values were increasingly lower so that the two curves diverged. In all patients, Ca45 specific activities in the serum were consistently greater than those in the urine at corresponding times (Table V) . The ratio of serum to urine values differed in the various disease states. For euthyroid subjects, the ratio was of the order of 1.30; in thyrotoxicosis, 1.54; in myxedema, 1.18; and in the two patients with Paget's disease, ratios of 1.77 and 3.86 were found. In the patient with idiopathic progressive osteoporosis, the ratio was 1.39; and in Patient L.L., who had osteoporosis of the "postmenopausal" type, a ratio of 1.80 (while receiving estrogen) fell to 1.49 after therapy was omitted.
Rate constants, coefficients and compartment sizes. There was no difference between the rate constants for Ca45 and Sr85, either in first or second exponential components of the serum or in urine curves (Table VI) . In the third component of the respective curves, Sr85 rate constants were suggestively larger than Ca45 values.
Coefficients and compartment sizes varied significantly in the different disease states. The differences were largest in the third compartment. Third compartment data based on urine measurements showed that Sr85 values paralleled those of Ca45 (Table VII) . Compartment sizes based on the serum curves were essentially the same for each isotope in each individual case (Table VIII) .
Calcium "pools." Expressing the data in terms of sequential pool sizes indicated the rapidity and extent to which either isotope entered the body calcium spaces. When the Ca45 data from urine measurements were employed, the "pool" sizes at three-day intervals ( Figure 7) were in good agreement with those found in similar patients previously reported from this laboratory (1). Papillon (3) reported that a "certain amount" of this element could be substituted for the calcium normally present in bone. A few years later Konig (4) found that ingested strontium was deposited in bone. In 1883, Ringer and Sainsbury (5) demonstrated that strontium was similar to calcium ion in its action on the contractility of the ventricle of the frog's heart. Subsequently it has been found that strontium prevents and con- trols parathyroid tetany (6) , stimulates activity of the uterus (7) and is effective in blood clotting (8) .
Although the human skeleton contains only traces of strontium (9, 10) , under suitable circumstances it can store appreciable amounts of this element (11, 12) . As (17) (18) (19) .
Despite these similarities strontium cannot serve the purpose of lime salt in bone. Shipley and Park, extending Lehnerdt's earlier work (20) , showed that when strontium completely replaces calcium in an otherwise adequate diet, "strontium" rickets develops (21) . Von Hodel's finding that strontium is preferentially excreted by the kidney has been confirmed many times (22) . Gastrointestinal absorption seems to favor calcium over strontium by a factor of about 2 (23) . Nevertheless, by eliminating the kidneys and minimizing the role of the gastrointestinal system function, except in Paget's disease. Retention of these two elements is a resultant of three main processes, viz., skeletal uptake, renal excretion and fecal elimination. In Paget's disease, skeletal uptake is exaggerated to the extent that relatively little of either labeled isotope is available for excretion. The kidneys compete more successfully with the skeleton in thyrotoxic patients than in the normal subjects, in clearing calcium and strontium from the serum. The result is a normal or low body retention. In myxedema, reduced skeletal uptake permits the excretory mechanisms more opportunity to clear the serum and, therefore, as in thyrotoxicosis but for different reasons, the body retention values are similarly low.
Spencer, Laszlo and Brothers found the plasma level of Ca45 higher than that of Sr85 throughout a 12-day study in a patient to whom both isotopes were administered orally. Blood data for the first 24 hours were not presented in their report (23) . Norris and Kisielski, on the other hand, found that the blood concentrations of Sr89 remained above those of Ca45 in mice receiving tracers intravenously (30) .
In all of the present studies the concentrations of Sr"5 and Ca45 in the serum were equal for at least the first 899 in attempts to quantitate calcium kinetics in the living organism. The application of these systems to data from experiments of diversified design accounts for the lack of uniformity in the published reports (1, 26, 28, 31, 32) . All of the curve analyses reported here were based on an arbitrary three-compartment system. No assumption was made that the values recorded were physiologically real. Rather, these analyses provided information for two considerations; first, they allowed for quantitative comparison of Sr55 and Ca45 kinetics in the same patient and secondly, they indicated that both labeled isotopes were similarly affected by specific bone disorders. Cortisone and Paget's disease. The findings in Paget's disease corroborate those of Albright and Henneman (33) in that cortisone suppressed the activity of the disease. The effect, while definite, was far from complete in restoring calcium exchange to normal.
Osteoporosis. Two patients with different types of osteoporosis were available for study.
A.L., a young male, had active progressive idiopathic osteoporosis, and L.L. had chronic disease of the postmenopausal type. In neither was the body retention of either labeled isotope particularly low. This is in accord with the findings by Heaney and Whedon (32) and of Nordin (34) that calcium "accretion" rates are normal in osteoporosis. Although Patient A.L. was in definite negative calcium and phosphorus balance (nitrogen balance being maintained), compartment sizes and "calcium pools" were normal.
The value of estrogen therapy in "postmenopausal" osteoporosis is difficult to assess. Animal experimentation has not been helpful, because the effect of this steroid varies in different species (35) (36) (37) cient period of timie to insure waning of any estrogenic effect (33) . The difference between the means of the calcium balance during the control and the treatment periods was significant (p < 0.05). The balance data for calcium and phosphorus are in good agreement with those of Reifenstein and Albright and demonstrated diminished calciuria and phosphaturia during estrogen therapy. However, the fact that Ca45 and Sr85 data showed no differences in skeletal kinetics between the control and estrogen therapy studies suggests that the effects of estrogen are extraosseous.
Ca45 serum and urine specific activities. Serum Ca45 specific activities consistently higher than corresponding urine values were observed in all cases (Table V) . This finding was unexpected and is not in accord with those of others. Most investigators have reported that Ca45 specific activities in urine and serum are similar (32, 40) . In most of these studies both serum and urine determinations are reported only for the first several days, when both values are changing rapidly. Since serum sampling is essentially instantaneous, urine specific activities determined on collections made over fixed periods of time, and plotted at the midpoint of the period, are erroneously elevated. This is especially true when the urine values are changing rapidly. Bronner, Benda, Harris and Kreplick, in a report of a case of gargoylism noted that "the corresponding values for urine tend, perhaps, to be lower than those for the serum" (41) . A review of Baker's Ca45 studies in patients with neoplastic disease disclosed that patients with hypercalcemia associated with metastatic calcification, with multiple myeloma, or with carcinoma metastatic to soft tissues and bone from breast and kidney, had identical Ca45 specific activity curves in serum and urine.5 Patients with metastatic breast carcinoma, but with normocalcemia, had serum to urine specific activity ratios of over 2. The most striking dissociation of serum and urine values occurred in a patient with carcinoma of the prostate, widespread bone metastases, and low to normal serum calcium concentrations. Ca45 specific activities in the serum were consistently five times higher than those in the urine during a nine-day study. In our own studies the ratios varied in different disease states and were highest in Paget's disease and thyrotoxicosis, "normal" in untreated osteoporosis and lowest (1.18) in myxedema. The patient with osteoporosis who received estrogen therapy was found to have a serum to urine Ca45 specific activity ratio of 1.80, compared with a control value of 1.49.
Nevertheless, the possibility remains that the observed discrepancy between Ca45 specific activities of blood and urine represents a systematic but undisclosed analytical error. In serum analysis, a positive error in Ca45 counts or a negative error in Ca40 measurement, or both, would result in a higher serum specific activity. Similarly, lowering of urine specific activities would result from a systematic negative error in Ca45 measurements or a positive error in Ca40 determinations, or both. A search for such a source of error has not been fruitful. Recovery measurements for Ca40 in serum and urine gave excellent validation of the methods used. The fact that the highest ratios of serum to urine specific activity appeared at lowest values for urine specific activity suggests a systematic error in radioactive isotopic determinations when these are present in low concentration, but recovery experiments with isotopic mixtures failed to disclose such an error. The discrepancy would not appear to be attributable to renal delay, because it was present long after administration of the labeled Ca45, when serum concentrations were changing very slowly from day to day. An alternative but seemingly less probable source of the discrepancy is that Ca40 and Ca45 are bound with different affinities to plasma protein, or are differentially excreted by the kidney, or are differentiated in some other way to account for the departure of the specific activity ratio from unity.
SUMMARY AND CONCLUSIONS 1. The distribution and excretion of Sr85 and Ca45 administered simultaneously and intravenously were studied in patients with thyroid and parathyroid disorders, osteoporosis, and Paget's disease. In all cases and at all times the body retention of Ca45 was more than Sr85 retention by a factor of 1.1 to 5.7.
2. Differential renal clearance of the two isotopes accounted for 1.9 to 8.1 times more Sr85 than Ca45 in the urine.
3. The amounts of each isotope in the feces were sizable, generally equal, and varied little in the different diseases studied, except in Paget's disease.
4. Calcium "pools" and compartment sizes as determined by either isotope proved to be sensitive indices of skeletal function. The largest values were found in Paget's disease and thyrotoxicosis and the lowest in myxedema.
5. One patient with thyroid cancer metastatic to bone showed no evidence of increased calcium turnover by any of the criteria employed.
6. A patient with hyperparathyroidism but no clinical evidence of bone disease showed no evidence of abnormal calcium or strontium dynamics.
7. In one patient with Paget's disease cortisone failed to suppress completely the activity of the disease as measured by Ca45 dynamics.
8. There was no unusual pattern of labeled isotope excretion in patients with osfeoporosis. Prolonged estrogen therapy in one patient with osteoporosis of the postmenopausal type effected no change in skeletal kinetics as measured by the metabolism of Ca45 or Sr85 but did effect a change in the serum to urine Ca45 specific activity ratio.
9. The observation that Ca45 specific activities were consistently greater in serum than in urine and the variation of serum to urine ratios in different disease states is discussed as representing either a true phenomenon or a systematic analytical error.
10. Sr85 qualitatively parallels Ca45 as an index of skeletal function in metabolic bone diseases.
